Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer - PubMed
4 days ago
- #immune-checkpoint-inhibitors
- #non-small-cell-lung-cancer
- #gut-microbiome
- Dual checkpoint blockade with ipilimumab plus nivolumab (I-N) shows limited efficacy in advanced NSCLC, benefiting only a subset of patients.
- High gut microbiota diversity correlates with improved outcomes in patients treated with I-N alone and increased CD8+ TIL infiltration.
- Responders to I-N alone exhibit enrichment of SCFA-producing bacteria, linked to favorable metabolic pathways for antitumor immune responses.
- No association between gut microbiota diversity and treatment efficacy was found in patients receiving I-N plus chemotherapy.
- Antibiotic use before treatment is independently linked to shorter PFS and OS across all treatment regimens.
- Baseline gut microbiota diversity may help identify patients likely to benefit more from I-N plus chemotherapy than I-N alone.
- Gut microbiota diversity and SCFA-producing bacteria are potential biomarkers for optimizing dual checkpoint blockade in NSCLC.